Search results
Showing 1 to 15 of 107 results for thyroid
This guideline covers investigating all suspected thyroid disease and managing primary thyroid disease (related to the thyroid rather than the pituitary gland). It does not cover managing thyroid cancer or thyroid disease in pregnancy. It aims to improve quality of life by making recommendations on diagnosis, treatment, long-term care and support.
This guideline covers diagnosis and management of thyroid cancer in people aged 16 and over. It aims to reduce variation in practice and increase the quality of care and survival for people with thyroid cancer.
All NICE products on thyroid cancer. Includes any guidance.
All NICE products on thyroid disorders. Includes any guidance.
Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults.
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over.
In development Reference number: GID-TA11531 Expected publication date: TBC
Evidence-based recommendations on selpercatinib (Retsevmo) for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over.
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
In development Reference number: GID-TA11160 Expected publication date: TBC
Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine (TA535)
Evidence-based recommendations on lenvatinib (Lenvima) and sorafenib (Nexavar) for progressive, locally advanced or metastatic differentiated thyroid cancer in adults who have had radioactive iodine.
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults.
Diabetes: thyroid disease screening (children T1DM) (IND312)
This indicator covers the proportion of children and young people aged under 18 years with type 1 diabetes who have been screened for thyroid disease in the previous 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
This indicator covers the percentage of patients with hypothyroidism, on the register, with thyroid function tests recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM100
Intraoperative nerve monitoring during thyroid surgery (IPG255)
Evidence-based recommendations on intraoperative nerve monitoring during thyroid surgery. This involves placing electrodes near the vocal cords to alert the surgeon when a surgical instrument comes close to either of the laryngeal nerves.
View recommendations for IPG255Show all sections
Sections for IPG255